












EAACI POSITION PAPER



Omics technologies in allergy and asthma research: An EAACI position paper

Urszula Radzikowska^{1,2}  | Katja Baerenfaller^{1,3}  | José Antonio Cornejo-García⁴  |
 Cagatay Karaaslan⁵  | Elena Barletta^{1,3} | Basak Ezgi Sarac⁵  | Damir Zhakparov^{1,3} |
 Alma Villaseñor^{6,7}  | Ibon Eguiluz-Gracia^{8,9}  | Cristobalina Mayorga^{8,9,10} |
 Milena Sokolowska^{1,2}  | Coral Barbas⁶ | Domingo Barber⁷  | Markus Ollert^{11,12} |
 Tomas Chivato^{7,13} | Ioana Agache¹⁴  | Maria M. Escribese⁷ 

¹Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland

²Christine-Kühne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland

³Swiss Institute of Bioinformatics (SIB), Davos, Switzerland

⁴Research Laboratory, IBIMA, ARADyAL Instituto de Salud Carlos III, Regional University Hospital of Málaga, UMA, Málaga, Spain

⁵Department of Biology, Molecular Biology Section, Faculty of Science, Hacettepe University, Ankara, Turkey

⁶Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain

⁷Institute of Applied Molecular Medicine Nemesio Diaz (IMMAND), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain

⁸Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain

⁹Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain

¹⁰Andalusian Centre for Nanomedicine and Biotechnology – BIONAND, Málaga, Spain

¹¹Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg

¹²Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, Denmark

¹³Department of Clinic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain

¹⁴Transylvania University, Brasov, Romania

Correspondence

Maria M. Escribese, Universidad CEU San Pablo, Urb. Monterprincipe s/n, Edificio MED. Despacho 2.01, 28668 Madrid, Spain.
 Email: mariamarta.escribesealonso@ceu.es

Funding information

This work was supported by the TF omic technologies in allergy research funded by EAACI

Abstract

Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. The increasing availability of high-throughput omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics allows studying biochemical systems and pathophysiological processes underlying allergic responses. Additionally, omics techniques present clinical

Abbreviations: MS, mass spectrometry; NGS, next-generation sequencing; PTM, post-translational modification.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

applicability by functional identification and validation of biomarkers. Therefore, finding molecules or patterns characteristic for distinct immune-inflammatory endotypes, can subsequently influence its development, progression, and treatment. There is a great potential to further increase the effectiveness of single omics approaches by integrating them with other omics, and nonomics data. Systems biology aims to simultaneously and longitudinally understand multiple layers of a complex and multifactorial disease, such as allergy, or asthma by integrating several, separated data sets and generating a complete molecular profile of the condition. With the use of sophisticated biostatistics and machine learning techniques, these approaches provide in-depth insight into individual biological systems and will allow efficient and customized healthcare approaches, called precision medicine. In this EAACI Position Paper, the Task Force "Omics technologies in allergic research" broadly reviewed current advances and applicability of omics techniques in allergic diseases and asthma research, with a focus on methodology and data analysis, aiming to provide researchers (basic and clinical) with a desk reference in the field. The potential of omics strategies in understanding disease pathophysiology and key tools to reach unmet needs in allergy precision medicine, such as successful patients' stratification, accurate disease prognosis, and prediction of treatment efficacy and successful prevention measures are highlighted.

KEYWORDS

allergy, biomarker, omic, precision medicine, systems biology

1 | INTRODUCTION

Allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, and food allergy are heterogeneous and multifactorial inflammatory diseases affecting people all around the world, and the clinical manifestations vary among allergic patients.¹⁻⁴ The occurrence of allergic diseases is constantly increasing worldwide, and the underlying mechanisms remain to be further detailed.^{5,6} Although the development of allergic diseases has been well known to be influenced by both environmental and genetic factors, the interactions and possible outcomes of these factors are not fully understood.⁷ The complexity and heterogeneity of these diseases raise the challenge to diagnose and manage specific endotypes.^{8,9} Patients with allergic diseases and asthma have been reported to respond differently to the same treatment which may be caused by altered interactions between thousands of genes resulting in various subendotypes.¹⁰ The emergence of high-throughput omic technologies, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics, may allow to develop a molecular profile and deeper understanding of the pathogenesis of these diseases. These technologies can help to process and analyse a large amount of biological data, to interpret the potential outcomes and consequently decipher the mechanisms behind the development of these complex diseases.^{7,11} System-wide molecular profiling may have essential clinical implications, from discovery of new functional roles for a gene, a protein, or a metabolite involved in the disease progression and identification of

reliable biomarkers for disease endotypes, to new insights into disease pathobiology while aiding in the development of more precise therapeutic strategies for better disease management and control (Table 1).¹¹

2 | WHAT IS OMICS SCIENCE?

The phenotype of an organism, specific tissues, and individual cells in disease and health is determined by the molecular profiles of the individual cellular components present at a specific time under specific conditions. The genome is an organism's complete set of DNA that is relatively static and comprises all genes and noncoding DNA. The decision on what sequences of the DNA are accessible for transcription is determined by the epigenome, a set of modifications on the DNA including methylation, and on DNA-binding proteins, mainly histone proteins that carry a combination of several post-translational modifications (PTMs). The transcriptome is the set of all transcribed RNAs, which includes mRNAs, housekeeping RNAs such as rRNAs and tRNAs, and regulatory RNAs comprising long and short noncoding RNAs. The proteome comprises all the proteoforms, which are the sum of all molecular forms of a protein arising from a specific gene. The reason why a gene can give rise to several proteins are post-transcriptional processes such as differential splicing, variable promoter or start codon usage, and post-translational processes such as endoproteolytic cleavage, or PTMs. These mechanisms vastly

TABLE 1 Summary of methods, protocols, and data analysis pipelines most frequently used in omics approaches for allergic diseases research

	Methods and protocols	Data analysis pipeline	Mechanisms of allergic diseases
Genomics and transcriptomics			
Microarray	181,182	GWAS ¹⁸³ and RNA microarray bioinformatics ^{184,185}	Asthma, ^{89,186} Asthma and allergic rhinitis ^{187,188}
Sequencing	23,24,26,189	DNA- ²⁵ and RNA- ¹⁹⁰ sequencing bioinformatics	Asthma, ¹⁰² Food allergy, ^{191,192} Atopic dermatitis ⁸²
Single-cell sequencing	57,193	Single-cell sequencing bioinformatics ^{194,195}	Asthma and allergic rhinitis ⁸¹
Epigenomics			
HiChIP (chromosome structure)	62	ChIP-sequencing data analysis ¹⁹⁶	Asthma, Allergic rhinitis, Atopic dermatitis, Food allergy ^{29,60}
ATAC-sequencing (chromatin accessibility)	64	ATAC-sequencing data analysis ¹⁹⁷	
WGBS (DNA methylation)	69	Bisulphate sequencing data analysis ¹⁹⁸	Asthma, Allergic rhinitis, Atopic dermatitis, Allergic sensitization ^{58,59}
TAB-sequencing (DNA methylation)	68	TAB-sequencing data analysis ¹⁹⁹	
CUT&RUN (histone modifications)	65	CUT&RUN data analysis ²⁰⁰	
MS (histone modifications)	66	Histone modifications with use of MS ²⁰¹	Asthma and Allergic Rhinitis ⁶¹
Small-sequencing (short noncoding RNAs)	86	Small RNA-sequencing data analysis ²⁰²	
RNA-sequencing (long noncoding RNAs)	84	Long noncoding RNAs from RNA-sequencing data analysis ²⁰³	
Proteomics			
High-throughput protein identification, label-free quantification	121,122,126,128	Data analysis using similarity network fusion ¹²⁵	Allergen characterization ¹²⁹⁻¹³¹
N-glycan characterization	132		
Single protein quantification	120		
Metabolomics			
Proton nuclear magnetic resonance (1H-NMR)	204	Biobank procedures for metabolomics ²⁰⁵	Food allergy and Asthma ²⁰⁶
Liquid chromatography-MS (LC-MS)	207	Sample handling and preprocessing ²⁰⁸	Asthma ²⁰⁹
Gas chromatography-MS (GC-MS)	210	Quality assurance ²¹¹	Asthma severity ²¹²
Capillary electrophoresis-MS (CE-MS)	213	CEU Mass Mediator: metabolite identification ²¹⁴	Food allergy, Asthma ¹⁴⁰
Multiplatform	215	METLIN: metabolite identification ²¹⁶	Food-associated respiratory allergy ¹⁷²
Large-scale studies	217	XCMS-MRM and METLIN-MRM: targeted analysis ²¹⁸	Asthma risk ²¹⁹
Lipidomics	220	MS/MS deconvolution, ²²¹ Metaboanalyst, ²²² Biological pathways ²²³	

Abbreviations: ATAC-sequencing, Assay for Transposase-Accessible Chromatin using Sequencing; ChIP-sequencing, Chromatin immunoprecipitation followed by Sequencing; CUT&RUN, Cleavage Under Targets and Release Using Nuclease; HiChIP, Protein-centric Chromatin Conformation Method; MS, Mass Spectrometry; TAB-sequencing, Tet-assisted Bisulphate Sequencing; WGBS, whole-genome Bisulphate Sequencing.

expand the proteotype, which is the total of all proteoforms that define the cellular phenotype. Finally, the enzymatic or other biological activities of the different proteins, together with environment- and microbiota-delivered small molecules, determine the metabolome.

Thus, metabolites are then the final step of the process. Metabolome includes active metabolites as well as spent by-products of metabolic processes and their degradation substances. These different cellular components are tightly interconnected with positive and negative

feedback and feed-forward loops. The omics sciences aim at characterizing the entirety of these different cellular components, and their main disciplines include genomics, epigenomics, transcriptomics, proteomics, and metabolomics.

3 | PRECISION MEDICINE: THE IMPORTANCE OF ACCURATE PATIENTS' STRATIFICATION

Precision medicine-based approaches rely on validated biomarkers, and on cost-efficient sampling.¹² This requires a deep understanding of the immunopathology and of the phenotypic heterogeneity of clinical entities.¹³ The definition of extreme phenotypes may be helpful to characterize immune or metabolic pathways specifically linked to the corresponding endotype.¹³ For example, unfavorable prognosis-related biomarkers in allergic asthma cannot be identified before effectively differentiating allergic asthmatics from the rest of asthma patients with atopic sensitization,¹⁴ including both nonallergic atopic individuals and subjects in whom allergic mechanisms play a minor role. This prior differentiation will permit not only the elucidation of disease-specific pathways but also the identification of patients at higher risk of severity progression for whom a closer follow-up and an early therapeutic intervention would be warranted.¹⁵ Therefore, progress in precision medicine will necessarily mirror the advances in phenotype definition and in-patient stratification concerning prognosis and severity.¹³ Nevertheless, several issues may hamper the implementation of this approach. Allergic diseases are widely influenced by the specific exposome composition,¹⁶ which determines pronounced geographical variations in the relative prevalence and severity of certain phenotypes (regiotypes).¹⁷ In addition, it may explain why phenotypes and biomarkers validated for one area or one population might not be useful for other geographical areas.¹⁸ Moreover, allergen challenges are frequently needed to confirm the diagnosis of allergic diseases.^{19,20} In this regard, there is a need to develop new protocols with clinical applicability which allow a confirmation diagnosis of patients with severe phenotypes (e.g., bronchial allergen challenge protocol, that does not require the discontinuation of inhaled corticosteroids).^{19,20} In any case, severe cases of some extreme phenotypes can be hardly confirmed, which ultimately impairs the identification of clinically valid biomarkers.¹²

The concept of "personalized medicine" has been increasingly used in scientific literature, health care systems, and social media. The development of high-throughput technologies in omics sciences, and the analysis of their intensive associated data, have emphasized the great inter-individual variability in the biological response to disease and drug treatment. Therefore, clinical decisions could be conceivably adjusted or personalized considering the individual specific biochemical, physiological, and environmental characteristics. However, such a concept may be misleading as it could suggest the design of a unique treatment for each individual to maximize drug treatment efficacy. Thus, it would be more convenient to use "precision medicine," i.e., the ability to classify individuals into

subpopulations differing in their susceptibility to a particular disease, in their biology and/or prognosis, or in their treatment response.²¹ Ideally such classification should be based on the characterization of molecular phenotypes, i.e., the set of genomic/epigenomic, transcriptomic, proteomic, and metabolomic profiles/signatures underlying human pathologies and clinical outcomes. The identification of molecular phenotypes may help clinicians in the election of patient management strategies, including specific drug administration. The utility of this approach has been recently exemplified in other inflammatory diseases, such as inflammatory bowel disease and arthritis, setting the path from organ-based classifications toward those with a molecular basis. This would not only address common aspects in diseases affecting different organs but could also provide insights into mechanistic differences between pathologies involving the same organ.²²

4 | BASIC OMICS STRATEGIES

4.1 | Genomics and metagenomics

The genome encompasses the entire genetic material of cells/organisms, and genomics addresses the study of genes and their functions. Pharmacogenomics, the study of how genes influence drug response, could have a crucial role in avoiding therapeutic failure and, consequently, in precision medicine, as it aims to develop effective, safe medications and doses tailored to variations in a person's genes. However, despite precision medicine being the great promise of pharmacogenomics, its use in clinical settings is still in its infancy.

Limitations related to the high-cost and low-throughput of the Sanger DNA sequencing method have been overcome by parallel or next-generation sequencing (NGS) technologies,²³ which may use as a template both DNA or RNA (Figure 1). Two key applications of DNA-NGS are whole-exome and whole-genome sequencing (WES and WGS, respectively). WES targets approximately 22,000 human exons (protein-coding genes), whereas WGS encompasses the whole genome. Thus, while WES may identify exonic single nucleotide polymorphisms (SNPs), indels, structural, and copy number variants, WGS is a nontargeted strategy that also covers intergenic regions. NGS comprises both laboratory techniques and bioinformatics analysis of DNA-generated sequences (Figure 1A–C).^{23–26}

The first step is to prepare a DNA-fragment collection (library), representing a target region or the entire genome, through physical or enzymatic methods. These fragments are connected to platform-specific synthetic nucleotide sequences (adapters) to create known begins and ends and are further selected according to a platform-specific requirement.^{23–26} DNA fragment(s)-adapter(s) are linked to solid support containing sequences that are complementary to those from the adapters, and DNA is then amplified by PCR. The type of support and the amplification and sequencing methods are also platform specific.^{23–26} During PCR different signals that are interpreted by the sequencer as specific nucleotides are generated (by pyrosequencing or pH changes).^{23–26}




FIGURE 1 Main pharmacogenomics approaches. (A) *Sanger sequencing* characterises different size DNA fluorescently-labelled chains by capillary gel electrophoresis. (B) *Genome wide association studies*. DNA is loaded in a microarray containing probes for a genome-wide set of single nucleotide polymorphisms, and those surpassing a threshold value are considered statistically significant. (C) *Next-generation sequencing (NGS)*. DNA is fragmented and bound to sequence barcode-adapters, hybridised with oligonucleotides (primers), and clustered. Single-stranded molecules flip over and hybridise with adjacent primers, leading to bridge formation. A polymerase repetitively synthesises the reverse strand. Strands are linearised before sequencing, with DNA incorporating fluorescent dNTPs. Each base emits a specific, identifiable signal. A complete sequence is given after reads assembly. (D) *Main steps in NGS analysis*. Primary analysis includes signal analysis (detection and raw data evaluation), and base calling and quality scoring. This generates a FastQ file, containing information on base and sequence quality, GC content, sequence length distribution and duplication levels, overrepresented sequences and adapter content. Low-quality sequences and adapters are cleaned. Secondary analysis mainly implies reads alignment against the reference genome and variants calling. Tertiary analysis, which includes variant annotation and filtering, prioritisation, and data visualisation, tries to connect variants and clinical phenotypes. BAM, binary alignment map; dNTPs/ddNTPs, deoxynucleotide/dideoxynucleotide triphosphates. FASTQ, fast analysis sequences toolbox quality; SAM, sequence alignment map; VCF, variant calling format

Data generated by NGS require an in-depth bioinformatics data handling, which starts with signal analysis (raw data detection and evaluation), base calling (generation of legible sequencing reads), and scoring base quality (Figure 1D). After raw signal measurements, a fast analysis of sequences toolbox quality (FASTQ) file is usually provided as output, which also contains potential sequencing errors according to a logarithmic error probability called the Phred score.²⁵ The quality of the raw sequences may be assessed by different tools, with FastQC being one of the most commonly used, which provides information such as base and sequence quality, base/GC content, sequence length distribution, and duplications.²⁵ Low-quality sequences and adapters can be cleaned using different tools,

like Trimomatic, TopHat, and Cufflinks.^{25,27} Reads are aligned to the reference human genome, with Bowtie 2 being among the most used aligners.²⁵ *De novo* assembly, in which read assembling does not rely on an external reference genome, is less frequent in clinical genetics.²⁵ Post-alignment processing is performed to improve the accuracy and quality of downstream steps (duplicate reads removal, local realignment of reads, and base quality score recalibration), using tools like SAMtools and Genome Analysis Toolkit (GATK).²⁵ Such tools help also to identify variants (variant calling). Finally, identified variants are connected with the specific clinical phenotype through a process including variant annotation and filtering, prioritisation, and data visualisation. Variant annotation provides

biological information of all variants, including functionality, amino acid conservation, protein structure, and prediction of how they can affect structure/functionality. Among the most frequently used annotation tools are SIFT, PolyPhen-2, ANNOVAR, and variant effect predictor.²⁵ Additional information can be found through various genome browsers, such as Ensembl, UCSC, and 1000 Genomes Project.^{28,29} Recent, genomic studies in the field of allergic diseases are summarized in Table S1 (DNA-based approaches).

During the past two decades, a great interest has been devoted to metagenomics, i.e., the analysis of all genomes of the microbiota (metagenome). Microbiota refers to all the microorganisms living in a specific place of the body, which encompasses a diversity of bacteria, archaea, viruses, fungi, and protozoans.³⁰ In addition to the complexity of associations between humans and these microorganisms, research carried out in this field has also emphasised their essential role in preserving human health.³¹ Over recent years, a number of studies have focused on the utility of metagenomics for deciphering the underlying mechanisms in allergic diseases, with intriguing data available for atopic dermatitis,³² allergic rhinitis,³³ asthma,^{34,35} and food allergy,³⁶ among others. The main high-throughput sequencing technologies used in microbiota characterisation include PCR amplicon-based sequencing (16S and 18S rRNA and internal transcribed spacer, ITS, sequencing), DNA-based shotgun metagenomic sequencing, RNA-based metatranscriptomic sequencing, and virome sequencing.³⁷

16S rRNA sequencing consists in the amplification of the hyper-variable regions of the 16S ribosomal RNA subunit genes, which are unique for specific bacterial genera. Quality control evaluation of sequencing reads is similar to these already described.³⁸ Taxonomic assignment is usually based on sequence similarity or on the analysis of amplicon sequences before introducing amplification and sequencing errors, with different methods and packages being recently described.³⁷

Concerning fungi, the 18S rRNA amplicon sequencing, which also focusses on hypervariable regions, and sequencing the ITS region, a 500–700 bp nuclear ribosomal DNA sequence, are the methods most commonly used for their identification.^{39,40} In contrast to PCR-guided strategies, shotgun metagenomics sequencing does not require specific primers, avoiding potential biases, and allows the identification of all types of microorganisms, which makes it the most effective method for obtaining structural and functional information. After quality control examination, sequencing analysis may be performed through the alignment and reads comparison to known reference genomes or by database searching, or through *de novo* assembly; however, both approaches are recommended to be used to obtain most precise results.^{41,42}

The amplicon-based approach is not useful for viruses sequencing due to their great diversity and the lack of universal marker genes, so metagenomics sequencing is the preferred procedure. Previous to sequencing, for RNA viruses a reverse transcription step is needed to obtain cDNA as RNA is easily degradable. Once the reads have been obtained, quality control analysis includes the elimination not only of human sequence reads but also those of 16S and

18S rRNAs. Although an alignment-based method could be used, the number of available genomes is weak and deposited sequences may be not correctly annotated. Thus, *de novo* assembly is normally preferred.^{43–45}

4.2 | Epigenomics

Epigenomics is a branch of omics science that analyzes an epigenetic profile of a cell (epigenome).⁴⁶ Epigenetic regulation refers to the reversible alterations in gene expression that do not involve changes in the DNA sequence.^{46,47} Epigenetic re-arrangements include chemical modifications of DNA and DNA-related proteins (histones).^{28,46} The main mechanisms involved in the epigenome spectrum are (i) alterations in chromosomal structures, (ii) chromatin accessibility (iii) DNA methylation, and (iv) histone modifications, all of which regulate DNA accessibility and gene expression (Figure 2).^{28,46–48} Epigenetic processes control the functional output of the information stored in the genome and directly shape cell development, function, and fate.^{28,46}

Factors that affect epigenome profiles during the lifetime include developmental programs, differentiation, and pathophysiological mechanisms, circadian cycles, environmental exposures, including effects of host-microbiome profiles, and the internal hormonal and metabolic milieu.^{28,46,48,49} Epigenetic changes can be mitotically (cellular memory) or meiotically (parental imprinting) heritable and can be passed through generations.²⁸ Interestingly, already the prenatal and early postnatal period can influence the development of diseases such as allergy in adulthood.^{28,29} Several recent, epigenomic studies in the field of allergic diseases allowed identification of epigenetic signatures of asthma/allergy and are summarized in Table S2.^{50–57} Additionally, epigenetic mechanisms involved in the development, course, and control of allergic diseases are in detail reviewed elsewhere.^{29,47,58–61}

Epigenomes can be analyzed from a broad range of samples, including cells, tissues, and body fluids (Figure 2). Constant development in the field of omics research allows for sensitive and specific measurements from lower sample quantities. Depending on the scientific question, certain experimental and biostatistical pipelines for bulk or single-cell analysis can be implemented.⁴⁷ Understanding the proper technique prior to sample collection is crucial to obtain reliable data. Chromosome structures can be investigated with the use of HiChIP (protein-centric chromatin conformation method), which allows for analyzing the 3D architecture of chromatin in the chromosomes by capturing long-range interactions associated with a protein of interest (Figure 2A).⁶² Accessible chromatin (“open frames”) can be analyzed with the use of ATAC-seq (ATAC-seq).⁶³ ATAC-seq enables isolation of genome regions, which are available for the transcriptional machinery (Figure 2B).^{63,64} Histone PTMs apply to chemical alterations (methylation, acetylation, phosphorylation, sumoylation, and/or ubiquitylation) of genome-associated proteins, which modulate histone-DNA interactions and lead to opening or closing of chromatin and changes accessibility.




FIGURE 2 Graphical summary of novel methods used in epigenetic research. (A) Chromosome structures can be assessed with use HiChIP. (B) Chromatin accessibility is widely investigated by ATAC-sequencing. (C) Global histone modifications can be analyzed with use of MS, whereas CUT&RUN method is used for PTMs-specific gene expression regulation. (D) 5mC and 5hmC DNA methylation can be assessed with use of whole-genome bisulphate sequencing and TAB-seq methods, respectively. Detailed protocols and data analysis pipelines are included in Table 1. PTM, post-translational modification; WGBS, Whole-genome bisulphate sequencing; ncRNA, noncoding RNA

The CUT&RUN (Cleavage under targets and release using nuclease) technology uses antibodies targeting the specific PTMs of interest and allows for genome-wide profiling of histones.^{63,65} Mass spectrometry (MS) approaches allow to obtain a comprehensive and quantitative view of histone PTMs (Figure 2C).⁶⁶ DNA methylation (addition of methyl-5mC or hydroxymethyl-5hmC group inside and outside CpG islands) is responsible for the silencing of gene transcription.⁶⁷ TAB-seq (Tet-assisted bisulfate sequencing)

is a novel technique allowing to determine the abundance of 5hmC modifications across the genome (Figure 2D).⁶⁸ 5mC modifications can be assessed with use of whole-genome bisulphate sequencing (WGBS).⁶⁹ However, methylation profiling microarrays are the most frequently used technology in the allergic diseases research field (Table S2).^{50–57} Notably, the recent development of the CRISP/Cas9 technology provides a powerful editing and control toolbox for obtaining a better understanding of epigenetic mechanisms.^{47,70} For a

broad overview of all available approaches in epigenetics, refer to the mentioned references.^{47,60,63,71-74}

Epigenomics is a dynamically developing field of research, which allows understanding the functional regulation of gene expression, and its consequences for health and disease. Epigenetic therapies (epidrugs) are already approved in cancer treatment.^{75,76} Controlled alteration of epigenetic mechanisms in allergic patients has potential for clinical applications and needs further investigations.⁷⁷

4.3 | Transcriptomics

The transcriptome represents the set of all RNA molecules, including protein-coding RNAs and noncoding RNAs (ncRNAs) produced by transcription of the genome under a specific circumstance, in a specific tissue or cell.⁴ ncRNAs are defined to not encode proteins longer than 100 amino acids and can be divided into two groups: (i) short (represented here by microRNAs) and (ii) long noncoding RNA (lncRNAs). Peripheral blood, bronchial tissue, and sputum cells are the primary sources used for transcriptomic profiling in asthma and allergic diseases (Figure 3A).⁷⁸

Nowadays, three methods are mainly used in transcriptome analyses. The microarray technique involves the hybridisation of oligonucleotide probes deposited in a predetermined spatial

order to their corresponding cDNA fragments derived from cellular RNAs (Figure 3B).¹¹ This approach is relatively cost-effective, but is dependent on predefined probe sets, which limits its usability. Furthermore, the hybridization-based approach suffers from background noise, due to cross-hybridisation and limited dynamic range.¹¹ In recent years, next-generation RNA-seq technology has been widely used in transcriptome profiling, as it is more accurate and sensitive technique and requires less RNA sample (Figure 3C). Unlike microarrays, this technology does not depend on predesigned probes and therefore enables rapid, deep, and high-throughput transcriptome analyses, studying transcription initiation and alternative splicing events, and cataloguing antisense and gene fusion transcripts.^{79,80} The latest approach is single-cell RNA-seq, which includes the isolation of a single cell from a population and then assesses the gene expression differences between individual cells. This approach offers the opportunity to uncover rare events in a population that can be overlooked when the whole population is considered.^{72,81,82} Single-cell transcriptomics, when combined with other single-cell omic techniques including genomics, epigenomics, and proteomics in the same cell, create a great potential to discover new cell types and states.⁸³ MicroRNAs can be identified with the use of small RNA sequencing, whereas lncRNAs that are often capped and polyadenylated can be analyzed together with mRNAs with the use of standard RNA-seq approaches (Figure 3D).⁸⁴⁻⁸⁶




FIGURE 3 Graphical summary of transcriptomic analyses in allergic diseases. (A) Samples including bronchial tissue, blood, atopic lesions, BALF, and nasal lavage are collected from both healthy and diseased individuals. RNA isolation can be performed either directly from samples or isolated cells. RNA extraction from isolated single-cell populations can be performed to investigate a cell-based transcriptomic alteration. Isolated RNA samples are subjected to microarray (B), or RNA Seq (C) depending on the purpose. Gene expression levels of the samples are determined by high throughput sequencing and the transcriptomics data are processed, analyzed and interpreted by means of bioinformatics tools. (D) Noncoding RNA (ncRNA) expression determination is divided into Short ncRNA sequencing (left panel) and long ncRNA sequencing (right panel) methods. BALF, bronchoalveolar lavage fluid; FACS, fluorescence-activated cell sorting

Global transcriptome analysis in allergic diseases allows the identification of distinct biomarkers and endotypes.

Blood transcriptomics has been widely used in molecular analyses and assessing treatment responses in allergic diseases (Table S1, RNA-based approaches).^{4,87–89} Bigler et al. showed that genes associated with chemotaxis, migration, and myeloid cell trafficking were highly expressed in severe asthmatics, while genes associated with B lymphocyte development and hematopoietic progenitor cells and lymphoid organ hypoplasia showed decreased transcript expression according to pathway analyses. Subgroups among severe asthmatics showed different responses to oral corticosteroids.⁸⁹ Transcriptome profiling of nasal and bronchial tissues can be vital to develop a deeper understanding of the pathobiology of allergic diseases. Analysis of nasal epithelium collected from healthy individuals and allergic patients demonstrated striking differences with 94 transcripts differentially expressed in allergic patients in nonchallenged (winter) and 85 in challenged (spring) season.⁹⁰ Interestingly, upon house dust mite stimulation nasal epithelium of allergic individuals showed enrichment in protease inhibitor activity pathway (GO:0030414), with upregulated expression of SPINK5, SPINK6, SPINK7, SERPINB3, WFDC5, and downregulation of C3.⁹¹ Transcriptomic analyses of bronchial tissue have been performed to identify different endotypes and potential biomarkers, predicting treatment response in allergic diseases, especially in asthma.^{92–95} For example, Singhanian et al. stated that activated T cells might be responsible for neutrophilic inflammation and for the steroid insensitive IL-17 response in severe asthma.⁹⁶ Nie et al. analysed ten eligible bronchial tissue microarray datasets, revealing that *CEACAM5*, *CLCA1*, *POSTN*, *CPA3*, *SERPINB2*, *KRT6A*, *CD44*, and *MUC5AC* transcript expression was up-regulated, while *LTF* and *MUC5B* expression was down-regulated in asthmatics.⁹⁷ Sputum is another crucial source for transcriptomic analyses^{98–102} and in asthmatic patients can be used in asthmatic patients to unravel asthma endotypes. A study revealed that *CLC*, *CPA3*, *DNASE1L3*, *IL1B*, *ALPL*, and *CXCR2* transcript levels could discriminate inflammatory asthma phenotypes. The transcript levels of these genes were also reported to predict the response to inhaled corticosteroid treatment.¹⁰³ Overall, eosinophilic airway inflammation (also called T2-high) has been correlated with higher expression of *CLC*, *CLCA1*, *CPA3*, *DNASE1L3*, *POSTN*, and *SERPINB2*; neutrophilic airway inflammation has been associated with higher expression of *IL1B*, *ALPL*, and *CXCR2*.^{13,97,103} Numerous studies have reported that ncRNAs, including miRNA and lncRNAs also contribute to the pathogenesis of asthma.¹⁰⁴ An RNA-seq analysis revealed that lncRNAs, including LINC01771, LINV02145, and GUSBP2 are closely associated with asthma-related genes, and participate in apoptosis, inflammation, and the immune response,¹⁰⁵ suggesting that ncRNAs are involved in asthma pathogenesis.

Profiling gene expression may unveil the molecular mechanisms in allergic diseases. Transcriptomic studies investigating treatment responses have been reported.^{106–108} Thus, integrating transcriptomics and the other complementary omics technologies in daily clinical practise may contribute to tailor-made therapies for each individual by predicting potential efficiency and responses to a

particular treatment. This will allow us to develop a deeper understanding of why treatment approaches fail to treat some patients and how to tailor treatments to individual patients.

4.4 | Proteomics

Proteomics aims at characterizing proteins, and proteomics methods can be broadly divided into a small subset, or multiplex protein analyses, and MS-based proteomics (Figure 4).

4.4.1 | MS-based and non-MS-based proteomics approaches

Methods aimed at characterizing a defined subset of proteins are usually based on antibody recognition followed by read-out using conjugated secondary antibodies producing a signal (Figure 4A–C). In novel multiplex immunological assays (e.g., Olink) a defined panel of target proteins are bound by pairs of antibodies conjugated with oligonucleotides, and therefore allow to work with microliters of the sample.¹⁰⁹ In MS-based proteomics, top-down and bottom-up approaches can be distinguished. In top-down proteomics, single intact low-mass proteins are analyzed to detect protein isoforms and PTM patterns. In the much more widely applied bottom-up proteomics, the proteins are subjected to proteolytic digestion to form peptides before MS analysis.

4.4.2 | Bottom-up proteomics requires protein extraction, proteolysis, peptide purification, and separation

At the outset of a proteomics experiment are sample lysis and protein extraction. Proteins can be isolated from body fluids, cells, or tissues, and either total protein extracts can be analyzed, or sub-fractions such as protein interaction partners or post-translationally modified proteins (Figure 4A,B). Further sample preparation usually involves reduction of disulfide bonds followed by carbamidomethylation of cysteine sulfhydryl groups, and protein digestion with an endoproteolytic enzyme such as trypsin, either in-gel after electrophoretic separation on 1D- or 2D-SDS-PAGE,¹¹⁰ in-solution or on columns. Before the purified and resuspended peptides enter the MS, they are usually fractionated using a reverse phase C18 columns (Figure 4D–E).

4.4.3 | At the mass spectrometer: peptide ionization, mass analysis of the ions, and ion detection

In electrospray ionization (ESI), the positively charged peptide droplets emerging from the tip of the column are evaporated until the peptides are getting into the gas phase. The peptide ions then enter




FIGURE 4 The proteomics workflow. Protein isolation, quantitation and extraction (A); protein separation, enrichment and depletion techniques (B); immunoassays (C); peptide formation through enzymatic digestion (D); chromatography techniques (E); mass spectrometry (F); peptide and protein identification (G); targeted and untargeted protein identification and quantification methods (H); label-free and label-based quantification technologies (I); statistical and functional analysis of the identified and quantified peptides and proteins (J). BSA, bovine serum albumin; CE, capillary electrophoresis; DDA, data-dependent acquisition; DIA, data-independent acquisition; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting; GC, gas chromatography; HCD/CID, higher-energy collisional dissociation/collision induced dissociation; HRP, horseradish peroxidase; IEF, isoelectric focusing; iTRAQ, isobaric tags for relative and absolute quantitation; LC, liquid chromatography; MALDI, matrix-assisted laser desorption ionization; PBMCs, peripheral blood mononuclear cells; PMF, peptide mass fingerprinting; POI, protein of interest; PRM, parallel reaction monitoring; PTMs, post-translational modifications; SILAC, stable isotope labeling by amino acids in cell culture; SRM, single reaction monitoring; SWATH, sequential window acquisition of all theoretical fragment ion spectra; TAILS, terminal amine isotopic labeling of substrates; TMT, tandem mass tag; TOF, time-of-flight

the MS, where their mass over charge (m/z) is determined making use of physical properties of the ions that are directly related to their m/z , such as their time-of-flight (TOF), stability in an electromagnetic field (Ion Trap), or rotation around an electromagnetic rod (Orbitrap). This results in the generation of a MS1 mass spectrum in which each of the peaks represents an ion with a specific m/z . In order to get sequence information for the measured ions, tandem MS (MS/MS or tandem MS) is performed. To this end, selected ions are isolated inside the mass spectrometer and then fragmented, typically through collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD). The energy of the collision is thereby set such that each peptide molecule should only break once, usually at the amide peptide bond. The m/z of the fragment ions is then recorded in the MS2 or fragment spectrum (Figure 4F).

4.4.4 | From MS spectra to list of identified and quantified peptides and proteins

Assignment of peptide sequences to the measured spectra is then performed by protein database-dependent searching with search algorithms that implement different methods (Figure 4G).¹¹¹ While in data-independent acquisition (DIA) usually the most intense ions in MS1 are selected and fragmented, data-dependent acquisition (DDA) focuses on predefined lists of peptides. In selected reaction monitoring (SRM), the mass spectrometer only measures ions that are comprised in a predefined list of peptides, and a number of specific fragment ions for each peptide. In parallel reaction monitoring (PRM), the full fragment spectra of the predefined peptides are monitored.^{112–114} In the DDA method termed SWATH, all precursors found in a specific

m/z isolation window are selected and fragmented, and all the fragments are recorded in a complex fragmentation spectrum before moving on to the subsequent isolation window. Deconvolution of the complex fragment spectra is then based on fragmentation information contained in spectral libraries (Figure 4).^{115,116} For MS-based protein quantitation, label-based and label-free methodologies are available. Label-free methods rely on differences in the areas under elution curves of the peptides over retention time or on the number of MS2 spectrum counts.¹¹⁷ Labelling of either proteins or peptides is a common quantitation strategy. Peptide labelling often makes use of mass-balanced label sets with different reporter ions such as iTRAQ or TMT.^{114,118} A method for labelling proteins is SILAC in which proteins in cultured cells are first labelled with isotopically light, heavy, or medium-heavy amino acids before the cultures are perturbed to induce changes in the proteome (Figure 4).¹¹⁹

4.4.5 | Biological data mining

Typical proteomics experiments will generate lists of identified proteins for which fold changes between experimental conditions are indicative for the quantitative changes. A series of subsequent statistical and functional analyses then serves to obtain relevant information from these lists that addresses the scientific questions and hypotheses of the experiments (Figure 4J).

The considerable improvements regarding sensitivity, applicability, and versatility of proteomics technologies have led to their wider application also in the field of allergy (Table S3). Recent applications range from the quantification of one single protein in bronchoalveolar lavage,¹²⁰ to high-throughput protein identification in tear fluid,¹²¹ skin swabs,¹²² sputum,¹²³ serum,^{124–127} or even mouse lungs.¹²⁸ In addition, proteomics methods were applied to identify immunoreactive proteins,^{129–131} or changes in N-glycan modification patterns.¹³² With this broad spectrum of potential applications, it is expected that proteomics results will be central to many future research studies in the allergy field.

4.5 | Metabolomics

Metabolomics is the science focused on the study of metabolism in living organisms. The molecules that comprise the metabolic pathways are called metabolites. These are involved in biological functions and cellular processes, thus, can reveal the relationship between metabolism and phenotype. The metabolism under specific biological conditions, such as a disease can be altered, leading to the dysregulation of some metabolites; glucose in diabetes would here be a classical example. Among the metabolites, the studying of the lipids—lipidomics—has become an important field, as lipids have important roles in immune response regulation, and participate in cell signaling, growth, differentiation, and apoptosis.¹⁴ They have also shown to be altered in atopic dermatitis and asthma.^{133–135} As an example, ceramide was elevated in mice lungs after allergen

challenge, contributing to reactive oxygen species generation, apoptosis and neutrophilic infiltrate, which characterize the severe asthmatic phenotype.¹³⁶

Metabolomics studies can be carried out either in noninvasive samples such as urine, faeces, saliva, and breath, in minimally invasive samples such as blood (serum and plasma) or in tissue biopsies (Figure 5). Regarding faeces, this sample combines information from intestinal microbiota and host metabolisms. Additionally, microbiota in the lung, skin, or gut seems to play a key role in several allergic diseases (food allergy, atopic dermatitis, allergic rhinitis) and asthma.^{137–139}

Due to the diverse physicochemical properties of the different metabolites, metabolomics needs sophisticated analytical techniques, which permit the characterization of the metabolites (Figure 5). These techniques comprise MS—usually coupled with a separation technique for complex samples, such as liquid and gas chromatography (LC-MS and GC-MS, respectively)—and nuclear magnetic resonance spectroscopy (NMR).

Metabolomics approaches can be nontargeted and targeted. In the first one, the aim is to detect as many metabolites as possible in a single analysis in each patient from the study, and to identify those with statistical differences between the groups. In the targeted analysis, specific metabolites are selected based on previous knowledge are analyzed and frequently quantified. The nontargeted approach is often explorative with the aim to detect metabolic changes to better understand the molecular mechanisms in the pathology. This can result in the identification of potential biomarkers, which after validation can be used in the clinic for diagnosis or prognosis (Figure 5).

Understanding the molecular mechanisms is still the best way to improve diagnosis, prognosis, and therapeutic strategies. In this sense, metabolomics has been applied in the study of different asthma phenotypes, such as in paediatric food allergy with or without asthma,¹⁴⁰ and in adult obesity-associated asthma. Additionally, this is complemented with metabolomic studies of gut¹⁴¹ and airway³⁴ microbial-derived metabolites involved in asthma. The main metabolites identified across different studies from various body compartments were related to immune reactions, inflammatory processes, tricarboxylic acid cycle, oxidative stress, hypoxia, and lipid metabolism pathways (Table S4).

4.6 | Single-cell omics

Many inflammatory and structural cells are involved in the pathology of allergies and airway diseases. It is extremely important to understand the contribution of these cells and their responses to the onset, development, and severity of the disease. However, there are heterogeneity and unique variations among individual cells; therefore, cells in a population may not respond in the same way under every circumstance.¹⁴² Traditional sequencing approaches have great importance due to their ability to analyze bulk data from whole populations and represent a common pattern for various diseases. However, rare events in minor subpopulations can be overlooked when the whole population is taken into account. Single-cell multiomics approaches are




FIGURE 5 Metabolomics workflow for nontargeted analysis. After biological samples are collected, metabolites are extracted by removing interferences such as proteins, DNA or RNA. This step is usually performed by filtration or organic solvent addition. Metabolite extraction can use of additional steps of the sample preparation such as centrifugation, sonication or chemical derivatization according to the analytical technique that will be used. The analytical techniques more often used are mass spectrometry (MS) and nuclear magnetic resonance as they provide structural information. Usually MS is coupled with separation techniques. All of the instruments provide information about specific type of metabolites. After data processing, potential biomarkers are selected to be identified. Before metabolite selection, statistical analysis is performed applying multivariate analysis, using principal component analysis (PCA) and principal component analysis (PLS-DA) are carried out. After selection of statistically significant metabolites, these are identified usually by comparison to database information and by fragmentation. Metabolites are explained in the biological context

used to identify single-cell genome, transcriptome, proteome, or other multiomic information, including DNA or histone modifications, chromatin accessibility, small RNAs, and chromosomal conformation.¹⁴² Analyzing single-cell data allows for investigating cell-to-cell variations and evolutionary relationships, distinguishing unusual events in rare populations, identifying sub-populations or disease endotypes, and potentially leading to new biological discoveries. Single cells can be isolated using different methods, such as manual cell picking, magnetic- or fluorescence-activated cell sorting (MACS or FACS), laser capture microdissection (LCM), and microfluidics. The isolation method can be chosen according to different parameters required for research of interest.¹⁴³ Integrating single-cell multiomic analyses,

including metabolomics, transcriptomics, proteomics, and other cellular information allow to reveal the biological events occurring within a single cell. However, despite its obvious advantages, such as uncovering rare events and barcoded profiling, interpreting single-cell sequencing data is relatively more challenging than bulk sequencing.¹⁴⁴

5 | EXPOSOMICS: THE ROLE OF EXPOSOME IN PRECISION MEDICINE

Exposomics is a research field investigating the effect of the exposome (environmental, nongenetic exposures) on health and

disease.¹⁴⁵ The definition of exposome is very broad, therefore, multiple tools are required to sufficiently investigate those heterogeneous environmental exposures.^{146,147} Exposome is divided into two subgroups: internal and external exposome. Internal exposome can be assessed in various biospecimens with the use of described previously techniques, including genomics, transcriptomics, epigenomics, and proteomics.¹⁴⁶ Microbiome is another factor influencing internal exposome.¹⁴⁶ Notably, microbial dysbiosis is linked with an increased prevalence of chronic diseases, including allergy.¹⁴⁸ External exposome includes many indoor and outdoor exposures, such as diet, stress, lifestyle (smoking, pets, detergents), economic status, air quality, pollutants, climate, and social factors. Investigation of external exposome is very complex and often requires assessment of multiple exposures, using various techniques.¹⁴⁵ Questionnaires might be helpful to register diet preferences or smoking habits. However, preferably, should be coupled with a biological biomarker for validation (i.e., cotinine for tobacco).¹⁴⁵ Air sample quality can be measured by air samplers.¹⁴⁶ Social, cultural, and lifestyle data can be collected from social media platforms, smartphone-linked diaries, and other wearable devices (smartwatches).^{145,146} Protocol integrating biotic and abiotic exposures has been recently published.¹⁴⁹ Exposome has a significant impact on the development of allergic diseases.^{146,150,151} Integrating exposome into the concept of precision medicine will further improve patients' diagnosis and treatment.

6 | SYSTEMS BIOLOGY: INTEGRATION OF OMICS AND NONOMICS DATA

The rapid growth of data acquisition techniques has made it possible to introduce Big Data into life science and biomedicine areas. Many different options in the design of precision medicine treatment

approaches and improved patient care are now becoming a reality (Figure 6).

Big Data in biomedicine can be separated into two large data categories: omics and nonomics data. Nonomics data can be described as a multitude of highly variable data including epidemiological information, clinical, laboratory test, imaging or morphologic parameters, environment biomonitoring, electronic health records, all registered by healthcare professionals. In contrast, omics data sets are obtained using high-throughput biological platforms and provide thousands of features characterising biological processes at different levels (DNA, RNA, proteins, or metabolites levels).¹⁵²

The heterogeneity of nonomics data poses a major challenge for data integration.¹⁵³ Only a minority of proposed models have a decent predictive ability that could be implemented in practice.¹⁵³ This obstacle arises from several important properties of both nonomics and omics data. First, nonomics data acquisition is usually not standardised. This can heavily affect data quality, which in turn will downgrade the modelling performance. Second, clinical features (e.g., degree of illness severity) are still usually subjectively defined, introducing biases into datasets. Another source of bias may appear at an evaluation stage as assessment of clinical variables depends on the skills and competencies of a healthcare professional. On the other hand, omics data are generally free of these biases, because they are normalized and homogenous within one dataset. However, omics data impose great challenges in data integration as well due to the complexity, heterogeneity, dynamics, uncertainty, and inherited high-dimensionality. The combined analysis of different omics datasets that aims at identifying complex interactions between all the features in the dataset regardless of their nature therefore usually requires custom analytical tools and is limited by the lack of experimental standardisation.² As the different omics data acquisition and analysis technologies are further developed, increased experimental




FIGURE 6 Systems biology in precision medicine. Precision medicine aims to stratify patients into clusters characterized by common clinical and biological features. This is possible through an in-depth understanding of molecular and phenotypic heterogeneity of allergic diseases. Both nonomics and omics data are powerful tools in the understanding and management of allergic diseases. Integration of clinical and high throughput data creates new opportunities to fully comprehend genotype-phenotype interactions in allergic patients, subsequently improving healthcare workflow, efficient diagnostics, and treatment

standardisation, and advanced data integration and modelling approaches are expected to enhance the usefulness of omics data sets in gaining biomedically relevant insights.

In order to overcome the challenges in integrating omics and nonomics data, several strategies have been developed¹⁵³ (Table S5). The most straightforward approach is independent data integration, when both omics and nonomics datasets are analysed separately, the most important variables are selected and integrated into a final model.¹⁵⁴ However, this method has a major downside as it does not consider interactions between different data sets are crucial in the context of biomedicine. During conditional modelling, omics variables are combined with clinical ones, and afterwards, dimensionality reduction is performed on the omics data set. The major drawback is that those techniques are computationally costly, requiring dedicated strong computers. Lastly, joint modelling on the combined datasets is a promising technique, even though the information on its application is quite scarce.¹⁵⁵⁻¹⁵⁷

After the data have been successfully integrated, the next step is to build a model for machine learning. This is a powerful approach that can be applied to a broad variety of tasks, whether it is to identify patterns associated with an illness, use as a diagnostic tool to predict disease status, or predict response to an intervention. The heterogeneous multilayered network (HMLN) has proven successful in integrating diverse biological data for the representation of the hierarchy of the biological system.¹⁵⁸ The HMLN provides unparalleled opportunities but imposes new computational challenges on establishing causal genotype-phenotype associations and understanding environmental impact, especially important for complex diseases like allergic diseases and asthma. Several other artificial intelligence approaches can be used depending on the purpose: disease subtyping, mechanistic insights, or biomarker prediction.^{158,159} Recent successful applications showed their utility in understanding the endotypes of asthma and allergy.¹⁶⁰⁻¹⁶⁴

Omics and nonomics data combination is still a challenging task, but the resulting inference or predictive models are quite promising. Potentially, such models can change the healthcare workflow, allowing for efficient resource management, improved diagnostics, and new insights on pathogenesis.

7 | CLINICAL APPLICATION AND CHALLENGES OF OMIC-BASED STUDIES

Initial omics studies have mainly relied on GWAS, which, despite their limitations, have shown to be a useful tool in pharmacogenomics. For example, in some populations they have led to specific recommendations before the administration of several drug types to prevent severe allergic reactions,¹⁶⁵ and some polymorphisms have been also associated with the response to inhaled corticosteroids^{166,167} and to long-acting β_2 adrenoceptor agonists in asthmatics.¹⁶⁸⁻¹⁷⁰

Nowadays, data from high-throughput omics technologies are substantially improving our knowledge on the mechanisms underlying allergic diseases, which should ideally shunt diagnosis and

treatment from a clinical phenotype-based approach towards a clinical endotype-based strategy. In fact, the advances achieved over recent years in molecular biology and bioinformatics have increasingly emphasised that biomarkers ascertained from a single "omics" may be insufficient to define all endotypes, which highlight the need of multiomics data integration not only for pathogenesis understanding but especially for predicting treatment response.² Although still in its infancy, some information concerning omics data integration is already available for allergy.¹³ Thus, the combination of metabolomics and transcriptomics has allowed the definition of different signatures in grass pollen mono and polysensitised patients receiving sublingual immunotherapy.¹⁷¹ Another study using both metabolomics and transcriptomics has also found specific patterns and biomarkers in severe grass-allergic patients, supporting a role for altered energy metabolism and systemic uncontrolled inflammation, which could be taken into account to decide which type of patients is eligible for immunotherapy.¹⁷² Finally, considering the complexity of phenotypes/endotypes, the great challenge for an effective multiomics data integration for valuating treatment options would need to include cohorts of extensively characterised patients and integrate both clinical and molecular information through modern bioinformatics tools, including machine learning.

There are several features, which need to be considered prior to the experiment and will help the researchers to plan and perform a successful multiomics analysis and draw a meaningful clinically applicable conclusion. It is recommended to perform the pilot study, as preliminary data will help to identify potential cofounders and sources of variations, which subsequently will help to assess the statistical power and sample size of planned analyses. Sample size in omic studies is always a limitation. Mainly because they are expensive techniques, complex to analyze, and need further validation and quantification. That is why omics analysis usually begins with small cohorts from pilot studies, to identify potential targets, biomarkers, or biological routes. Afterward, analytical validation takes place to ensure quantification of the molecular, and finally bigger cohorts are recruited to test the potential candidates. It is beneficial for researchers to use standard operating procedures (SOPs) and to consult experts in the field, to assist in practical aspects, such as correct sample collection, processing and storage, stability of the data sets over time/impact of applied therapies, and further data and analysis pipelines sharing. Validation is the final stage of the biomarker identification process and is necessary if the identified molecule is to reach clinical practice. The validation method involves conducting large collaborative studies with thousands of patients preferably. It directly tests each candidate biomarker with the collected new independent set of samples from the target population.¹³ In allergic disease some validations studied have been performed.^{173,174} However, now the identified biomarkers need to be translated into clinical practice. Translation of omics data into the clinical trials requires fulfillment of strict criteria and beforehand planning.¹⁷⁵ McShane et al highlighted the most important principles to performing saucerful omics-based clinical studies.^{175,176} Major ethical, methodological, and practical challenges that will need to be considered

TABLE 2 List of key ethical, methodological, and practical challenges to be addressed during omic data analysis¹⁷⁵⁻¹⁷⁹

	Challenges	Recommendations
Ethical	Patients' anonymity	Create a data base that links anonymous clinical data to omics data Include a data protection manager
	Responsibility for data generated by omic studies and communication with the individuals enrolled in the study	Provide clear identification of the person responsible for the study, responsible for data protection, and responsible for communication with enrolled subjects
	Informed consent documents	Clearly identify risks and benefits for enrolled subjects Provide detailed information regarding the study protocol, techniques, sample management and data analysis
Methodological	Sample management	Clear definition of sample roadmap including information regarding biobank storage, exact period of storage before destruction or additional informed consent for further experimental assessments and samples sharing Custody and conditions of sample storage
	Variations in assay procedures due to differences in technical protocols and analysis strategies	Standardization of technologies, data management and storage
Practical	Sample size	Perform a previous statistical analysis to ensure the justification of the number of samples/groups to obtain significant and reliable results
	Data interpretation	Define a protocol that contains clearly stated: objectives, methods, and analysis plan

are summarized in Table 2.¹⁷⁵⁻¹⁷⁹ Multidisciplinary collaborations between researchers, whether clinical, translational, or computer scientists are important and required to understand molecular phenotypes of the diseases and their potential in precision medicine.¹⁸⁰

8 | SUMMARY AND CLOSING REMARKS

Omic data are generated by high-throughput biotechnological platforms delivering hundreds of thousands of raw (nonelaborated) variables that have revolutionized biomedical research. Most of the studies are using a single omic approach to characterize biological features. Genomics, epigenomics, transcriptomics, proteomics, and metabolomics have been widely applied to identify biological variants (e.g., biomarkers and biological pathways), to characterize complex biochemical systems, and study pathophysiological processes. The potency of omic analysis will significantly increase if we are able to integrate them to generate a complete molecular profile of what is happening in a specific sample. Connections between genes and their outputs can provide some clues to what's happening in complex and multifactorial diseases as is the case of allergy and asthma. Furthermore, integrating omics datasets with nonomics data can reveal a much more complete view of biological activities and will allow us to classify and identify biomarkers, and predict disease progression and prognostic risk. Together, these approaches will provide the opportunity to get insights into biological systems of health and disease, and to conduct precision medicine.

ACKNOWLEDGEMENTS

The authors would like to thank the European Academy of Allergy and Clinical Immunology (EAACI) for support enabling the development

and publication of this paper. Figures created with Biorender.com Open access funding enabled and organized by ProjektDEAL.

CONFLICT OF INTEREST

AV is a Secretary of the EAACI IG on Allergy Diagnosis & Systems Medicine. CK is a member of the EAACI working group Genomics and Proteomics. IA is an Associate Editor of Allergy and CTA. KB reports: The Center for Precision Proteomics providing partial salary funding is funded through the Swiss canton of Grisons. Salary payments are made through the institution and are part of the regular salary. KB has been funded by the Earth Vision nonprofit corporation for chairing an event, performing a study and manuscript writing. The funding has been made to SIAF; the resulting manuscript has been published <https://doi.org/10.3390/microorganisms8040498>; the topic has no overlap with the study presented here. KB is a member of the board of directors of the Swiss Institute of Bioinformatics, member of the EAACI working group Genomics and Proteomics and president of the bioinformatics intersection of LS2 and member of LS2. MME is a Chair of EAACI WG on Genomics and Proteomics and report lecture fees from Diater and Stallergenes. MS reports grants from SNSF, GSK, Novartis; payments from AstraZeneca, and position of European Academy of Allergy and Clinical Immunology (EAACI) Basic and Clinical Immunology Board Secretary. MO reports personal consulting honoraria received from Hycor Biomedical; Member-at-Large 2019-2022, Executive Committee, European Academy of Allergy and Clinical Immunology (EAACI). UR is a Secretary of the EAACI WG on Genomics and Proteomics. All other authors report no conflict of interest regarding this manuscript.

ORCID

Urszula Radzikowska  <https://orcid.org/0000-0002-7341-9764>

Katja Baerenfaller  <https://orcid.org/0000-0002-1904-9440>

José Antonio Cornejo-García  <https://orcid.org/0000-0003-3465-8735>

Cagatay Karaaslan  <https://orcid.org/0000-0003-4857-0857>

Basak Ezgi Sarac  <https://orcid.org/0000-0003-1181-4598>

Alma Villaseñor  <https://orcid.org/0000-0002-6652-2739>

Ibon Eguiluz-Gracia  <https://orcid.org/0000-0002-3774-931X>

Milena Sokolowska  <https://orcid.org/0000-0001-9710-6685>

Domingo Barber  <https://orcid.org/0000-0002-5488-5700>

Ioana Agache  <https://orcid.org/0000-0001-7994-364X>

Maria M. Escribese  <https://orcid.org/0000-0001-5057-5150>

REFERENCES

- Thomsen SF. Epidemiology and natural history of atopic diseases. *Eur Clin Respir J*. 2015;2. doi:10.3402/ecrj.v2.24642
- Ghosh D, Bernstein JA, Khurana Hershey GK, Rothenberg ME, Mersha TB. Leveraging multilayered "omics" data for atopic dermatitis: a road map to precision medicine. *Front Immunol*. 2018;9:2727.
- Valero A, Quirce S, Davila I, Delgado J, Dominguez-Ortega J. Allergic respiratory disease: different allergens, different symptoms. *Allergy*. 2017;72(9):1306-1316.
- Park HW, Weiss ST. Understanding the molecular mechanisms of asthma through transcriptomics. *Allergy Asthma Immunol Res*. 2020;12(3):399-411.
- Ivanova O, Richards LB, Vijverberg SJ, et al. What did we learn from multiple omics studies in asthma? *Allergy*. 2019;74(11):2129-2145.
- Doll RJ, Joseph NI, McGarry D, Jhaveri D, Sher T, Hostoffer R. Epidemiology of Allergic Diseases. *Allergy and Asthma*. Springer International Publishing; 2019:31-51.
- Tang HFF, Sly PD, Holt PG, Holt KE, Inouye M. Systems biology and big data in asthma and allergy: recent discoveries and emerging challenges. *Eur Respir J*. 2020;55(1):1900844.
- Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines recommendations for severe asthma. *Allergy*. 2021;76(1):14-44.
- Donovan BM, Bastarache L, Turi KN, Zutter MM, Hartert TV. The current state of omics technologies in the clinical management of asthma and allergic diseases. *Ann Allergy Asthma Immunol*. 2019;123(6):550-557.
- Benson M. Clinical implications of omics and systems medicine: focus on predictive and individualized treatment. *J Intern Med*. 2016;279(3):229-240.
- Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. *J Allergy Clin Immunol*. 2015;135(1):31-42.
- Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma. *Allergy*. 2018;73(12):2290-2305.
- Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. *Allergy*. 2020;75(12):3039-3068.
- Sokolowska M, Rovati GE, Diamant Z, et al. Current perspective on eicosanoids in asthma and allergic diseases: EAACI task force consensus report, part I. *Allergy*. 2021;76(1):114-130.
- Muraro A, Fernandez-Rivas M, Beyer K, et al. The urgent need for a harmonized severity scoring system for acute allergic reactions. *Allergy*. 2018;73(9):1792-1800.
- Eguiluz-Gracia I, Mathioudakis AG, Bartel S, et al. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. *Allergy*. 2020;75(9):2170-2184.
- Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. *J Clin Invest*. 2019;129(4):1493-1503.
- Bogas G, Munoz-Cano R, Mayorga C, et al. Phenotyping peach-allergic patients sensitized to lipid transfer protein and analysing severity biomarkers. *Allergy*. 2020;75(12):3228-3236.
- Auge J, Vent J, Agache I, et al. EAACI position paper on the standardization of nasal allergen challenges. *Allergy*. 2018;73(8):1597-1608.
- Agache I, Bilo M, Braunstahl GJ, et al. In vivo diagnosis of allergic diseases--allergen provocation tests. *Allergy*. 2015;70(4):355-365.
- USNRC UNRC. Building a knowledge network for biomedical research and a new taxonomy of disease. *Toward precision medicine*. National Academies Press (US); 2011. doi:10.17226/13284
- Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases. Reply. *N Engl J Med*. 2021;385(21):e75.
- Metzker ML. Sequencing technologies - the next generation. *Nat Rev Genet*. 2010;11(1):31-46.
- Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. *Semin Thromb Hemost*. 2019;45(7):661-673.
- Pereira R, Oliveira J, Sousa M. Bioinformatics and computational tools for next-generation sequencing analysis in clinical genetics. *J Clin Med*. 2020;9(1):132.
- Arboleda VA, Xian RR. An overview of DNA analytical methods. *Methods Mol Biol*. 2019;1897:385-402.
- Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc*. 2012;7(3):562-578.
- Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. *Nat Rev Genet*. 2007;8(4):253-262.
- Agache I, Cojanu C, Laculiceanu A, Rogozea L. Genetics and epigenetics of allergy. *Curr Opin Allergy Clin Immunol*. 2020;20(3):223-232.
- Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. *Microbiome*. 2015;3:31.
- Gilbert JA, Lynch SV. Community ecology as a framework for human microbiome research. *Nat Med*. 2019;25(6):884-889.
- Tay ASL, Li C, Nandi T, et al. Atopic dermatitis microbiomes stratify into ecologic dermatotypes enabling microbial virulence and disease severity. *J Allergy Clin Immunol*. 2021;147(4):1329-1340.
- Zhu L, Xu F, Wan W, et al. Gut microbial characteristics of adult patients with allergy rhinitis. *Microb Cell Fact*. 2020;19(1):171.
- Chiu CY, Chou HC, Chang LC, et al. Integration of metagenomics-metabolomics reveals specific signatures and functions of airway microbiota in mite-sensitized childhood asthma. *Allergy*. 2020;75(11):2846-2857.
- Zhao H, Liu J, Zhu J, et al. Bacterial composition and community structure of the oropharynx of adults with asthma are associated with environmental factors. *Microb Pathog*. 2020;149:104505.
- De Filippis F, Paparo L, Nocerino R, et al. Specific gut microbiome signatures and the associated pro-inflammatory functions are linked to pediatric allergy and acquisition of immune tolerance. *Nat Commun*. 2021;12(1):5958.
- Gao B, Chi L, Zhu Y, et al. An introduction to next generation sequencing bioinformatic analysis in gut microbiome studies. *Biomolecules*. 2021;11(4):530.
- Zhou Q, Su X, Ning K. Assessment of quality control approaches for metagenomic data analysis. *Sci Rep*. 2014;4:6957.
- Nilsson RH, Anslan S, Bahram M, Wurzbacher C, Baldrian P, Tedersoo L. Mycobiome diversity: high-throughput sequencing and identification of fungi. *Nat Rev Microbiol*. 2019;17(2):95-109.
- Woo PC, Leung SY, To KK, et al. Internal transcribed spacer region sequence heterogeneity in *Rhizopus microsporus*: implications for molecular diagnosis in clinical microbiology laboratories. *J Clin Microbiol*. 2010;48(1):208-214.
- Junemann S, Kleinbolting N, Jaenicke S, et al. Bioinformatics for NGS-based metagenomics and the application to biogas research. *J Biotechnol*. 2017;261:10-23.
- Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. *Nat Biotechnol*. 2017;35(9):833-844.

43. Zarate S, Taboada B, Yocupicio-Monroy M, Arias CF. Human virome. *Arch Med Res*. 2017;48(8):701-716.
44. Garmaeva S, Sinha T, Kurilshikov A, Fu J, Wijmenga C, Zhernakova A. Studying the gut virome in the metagenomic era: challenges and perspectives. *BMC Biol*. 2019;17(1):84.
45. Carding SR, Davis N, Hoyles L. Review article: the human intestinal virome in health and disease. *Aliment Pharmacol Ther*. 2017;46(9):800-815.
46. Rivera CM, Ren B. Mapping human epigenomes. *Cell*. 2013;155(1):39-55.
47. Wang KC, Chang HY. Epigenomics: technologies and applications. *Circ Res*. 2018;122(9):1191-1199.
48. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH roadmap epigenomics mapping consortium. *Nat Biotechnol*. 2010;28(10):1045-1048.
49. Alenghat T, Artis D. Epigenomic regulation of host-microbiota interactions. *Trends Immunol*. 2014;35(11):518-525.
50. Acevedo N, Scala G, Merid SK, et al. DNA methylation levels in mononuclear leukocytes from the mother and her child are associated with ige sensitization to allergens in early life. *Int J Mol Sci*. 2021;22(2):801.
51. Hoang TT, Sikdar S, Xu CJ, et al. Epigenome-wide association study of DNA methylation and adult asthma in the agricultural lung health study. *Eur Respir J*. 2020;56(3):2000217.
52. Jiang Y, Forno E, Han YY, et al. A genome-wide study of DNA methylation in white blood cells and asthma in Latino children and youth. *Epigenetics*. 2021;16(5):577-585.
53. Qi C, Jiang Y, Yang IV, et al. Nasal DNA methylation profiling of asthma and rhinitis. *J Allergy Clin Immunol*. 2020;145(6):1655-1663.
54. Qi C, Vonk JM, van der Plaats DA, et al. Epigenome-wide association study identifies DNA methylation markers for asthma remission in whole blood and nasal epithelium. *Clin Transl Allergy*. 2020;10(1):60.
55. Kim KW, Park SC, Cho HJ, et al. Integrated genetic and epigenetic analyses uncover MSI2 association with allergic inflammation. *J Allergy Clin Immunol*. 2021;147(4):1453-1463.
56. Reese SE, Xu CJ, den Dekker HT, et al. Epigenome-wide meta-analysis of DNA methylation and childhood asthma. *J Allergy Clin Immunol*. 2019;143(6):2062-2074.
57. Cardenas A, Sordillo JE, Rifas-Shiman SL, et al. The nasal methylome as a biomarker of asthma and airway inflammation in children. *Nat Commun*. 2019;10(1):3095.
58. Alashkar Alhamwe B, Alhamdan F, Ruhl A, Potaczek DP, Renz H. The role of epigenetics in allergy and asthma development. *Curr Opin Allergy Clin Immunol*. 2020;20(1):48-55.
59. Kabesch M, Tost J. Recent findings in the genetics and epigenetics of asthma and allergy. *Semin Immunopathol*. 2020;42(1):43-60.
60. Zhang L, Lu Q, Chang C. Epigenetics in health and disease. *Adv Exp Med Biol*. 2020;1253:3-55.
61. Long A, Bunning B, Sampath V, DeKruyff RH, Nadeau KC. Epigenetics and the Environment in Airway Disease: Asthma and Allergic Rhinitis. In: Chang C, Lu Q, eds. *Epigenetics in Allergy and Autoimmunity*. Springer Singapore; 2020:153-181.
62. Mumbach MR, Rubin AJ, Flynn RA, et al. HiChIP: efficient and sensitive analysis of protein-directed genome architecture. *Nat Methods*. 2016;13(11):919-922.
63. Kleine-Weber H, Schroeder S, Kruger N, et al. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. *Emerg Microbes Infect*. 2020;9(1):155-168.
64. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: a method for assaying chromatin accessibility genome-wide. *Curr Protoc Mol Biol*. 2015;109(1):21 29 21-21 29 29.
65. Skene PJ, Henikoff JG, Henikoff S. Targeted in situ genome-wide profiling with high efficiency for low cell numbers. *Nat Protoc*. 2018;13(5):1006-1019.
66. Noberini R, Restellini C, Savoia EO, Bonaldi T. Enrichment of histones from patient samples for mass spectrometry-based analysis of post-translational modifications. *Methods*. 2020;184:19-28.
67. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. *Biology (Basel)*. 2016;5(1):3.
68. Yu M, Han D, Hon GC, He C. Tet-Assisted Bisulfite Sequencing (TAB-seq). In: Tost J, ed. *DNA Methylation Protocols*. Springer New York; 2018:645-663.
69. Ulrich MA, Nery JR, Lister R, Schmitz RJ, Ecker JR. MethylC-seq library preparation for base-resolution whole-genome bisulfite sequencing. *Nat Protoc*. 2015;10(3):475-483.
70. Xie N, Zhou Y, Sun Q, Tang B. Novel epigenetic techniques provided by the CRISPR/Cas9 system. *Stem Cells Int*. 2018;2018:7834175.
71. Kashi K, Henderson L, Bonetti A, Carninci P. Discovery and functional analysis of lncRNAs: methodologies to investigate an uncharacterized transcriptome. *Biochim Biophys Acta*. 2016;1859(1):3-15.
72. Liu K, Tong H, Li T, Wang X, Chen Y. Research progress in molecular biology related quantitative methods of MicroRNA. *Am J Transl Res*. 2020;12(7):3198-3211.
73. Dave VP, Ngo TA, Pernestig AK, et al. MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics. *Lab Invest*. 2019;99(4):452-469.
74. Pajares MJ, Palanca-Ballester C, Urtasun R, Alemany-Cosme E, Lahoz A, Sandoval J. Methods for analysis of specific DNA methylation status. *Methods*. 2021;187:3-12.
75. Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. *Epigenetics*. 2019;14(12):1164-1176.
76. Bates SE. Epigenetic therapies for cancer. *N Engl J Med*. 2020;383(7):650-663.
77. Potaczek DP, Harb H, Michel S, Alhamwe BA, Renz H, Tost J. Epigenetics and allergy: from basic mechanisms to clinical applications. *Epigenomics*. 2017;9(4):539-571.
78. Rodriguez MJ, Palomares F, Bogas G, et al. Transcriptional profiling of dendritic cells in a mouse model of food-antigen-induced anaphylaxis reveals the upregulation of multiple immune-related pathways. *Mol Nutr Food Res*. 2019;63(3):e1800759.
79. Nagalakshmi U, Wang Z, Waern K, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. *Science*. 2008;320(5881):1344-1349.
80. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet*. 2009;10(1):57-63.
81. Seumois G, Ramirez-Suastegui C, Schmiedel BJ, et al. Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma. *Sci Immunol*. 2020;5(48):eaba6087.
82. Mobus L, Rodriguez E, Harder I, et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. *J Allergy Clin Immunol*. 2021;147(1):213-223.
83. Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell states in health and in asthma. *Nat Med*. 2019;25(7):1153-1163.
84. Illott NE, Ponting CP. Predicting long non-coding RNAs using RNA sequencing. *Methods*. 2013;63(1):50-59.
85. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell*. 2007;129(7):1401-1414.
86. Eminaga S, Christodoulou DC, Vigneault F, Church GM, Seidman JG. Quantification of microRNA expression with next-generation sequencing. *Curr Protoc Mol Biol*. 2013;Chapter 4:Unit 4 17.
87. Li S, Todor A, Luo R. Blood transcriptomics and metabolomics for personalized medicine. *Comput Struct Biotechnol J*. 2016;14:1-7.
88. Yeh YL, Su MW, Chiang BL, Yang YH, Tsai CH, Lee YL. Genetic profiles of transcriptomic clusters of childhood asthma determine specific severe subtype. *Clin Exp Allergy*. 2018;48(9):1164-1172.
89. Bigler J, Boedigheimer M, Schofield JPR, et al. A severe asthma disease signature from gene expression profiling of

- peripheral blood from U-BIOPRED cohorts. *Am J Respir Crit Care Med*. 2017;195(10):1311-1320.
90. Joenvaara S, Mattila P, Renkonen J, et al. Caveolar transport through nasal epithelium of birch pollen allergen Bet v 1 in allergic patients. *J Allergy Clin Immunol*. 2009;124(1):135-142 e131. 121.
 91. Vroeling AB, Jonker MJ, Luiten S, Breit TM, Fokkens WJ, van Drunen CM. Primary nasal epithelium exposed to house dust mite extract shows activated expression in allergic individuals. *Am J Respir Cell Mol Biol*. 2008;38(3):293-299.
 92. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc Natl Acad Sci USA*. 2007;104(40):15858-15863.
 93. Yick CY, Zwinderman AH, Kunst PW, et al. Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. *Eur Respir J*. 2013;42(3):662-670.
 94. Modena BD, Bleecker ER, Busse WW, et al. Gene expression correlated with severe asthma characteristics reveals heterogeneous mechanisms of severe disease. *Am J Respir Crit Care Med*. 2017;195(11):1449-1463.
 95. Wilson SJ, Ward JA, Sousa AR, et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. *Eur Respir J*. 2016;48(5):1307-1319.
 96. Singhania A, Wallington JC, Smith CG, et al. Multitissue transcriptomics delineates the diversity of airway T cell functions in asthma. *Am J Respir Cell Mol Biol*. 2018;58(2):261-270.
 97. Nie X, Wei J, Hao Y, et al. Consistent biomarkers and related pathogenesis underlying asthma revealed by systems biology approach. *Int J Mol Sci*. 2019;20(16):4037.
 98. Baines KJ, Fricker M, McDonald VM, et al. Sputum transcriptomics implicates increased p38 signalling activity in severe asthma. *Respirology*. 2020;25(7):709-718.
 99. Rossios C, Pavlidis S, Hoda U, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. *J Allergy Clin Immunol*. 2018;141(2):560-570.
 100. Hodge S. Sputum transcriptomics: a tool for identifying gene expression underlying mechanistic pathways in severe asthma. *Respirology*. 2020;25(7):668-669.
 101. Kim BK, Lee HS, Sohn KH, Lee SY, Cho SH, Park HW. Different biological pathways are up-regulated in the elderly with asthma: sputum transcriptomic analysis. *Allergy Asthma Immunol Res*. 2019;11(1):104-115.
 102. Peters MC, Ringel L, Dyjack N, et al. A transcriptomic method to determine airway immune dysfunction in T2-High and T2-Low asthma. *Am J Respir Crit Care Med*. 2019;199(4):465-477.
 103. Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. *J Allergy Clin Immunol*. 2014;133(4):997-1007.
 104. Narozna B, Langwinski W, Szczepankiewicz A. Non-coding RNAs in pediatric airway diseases. *Genes (Basel)*. 2017;8(12):348.
 105. Zheng P, Huang C, Leng D, Sun B, Zhang XD. Transcriptome analysis of peripheral whole blood identifies crucial lncRNAs implicated in childhood asthma. *BMC Med Genomics*. 2020;13(1):136.
 106. Yick CY, Zwinderman AH, Kunst PW, et al. Glucocorticoid-induced changes in gene expression of airway smooth muscle in patients with asthma. *Am J Respir Crit Care Med*. 2013;187(10):1076-1084.
 107. Himes BE, Jiang X, Wagner P, et al. RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells. *PLoS One*. 2014;9(6):e99625.
 108. Choy DF, Jia G, Abbas AR, et al. Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma. *J Allergy Clin Immunol*. 2016;138(4):1230-1233 e1238.
 109. Rojahn TB, Vorstandlechner V, Krausgruber T, et al. Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis. *J Allergy Clin Immunol*. 2020;146(5):1056-1069.
 110. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. *Anal Chem*. 1996;68(5):850-858.
 111. Sadygov RG, Cociorva D, Yates JR 3rd. Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. *Nat Methods*. 2004;1(3):195-202.
 112. Meyer JG, Schilling B. Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques. *Expert Rev Proteomics*. 2017;14(5):419-429.
 113. Ronsein GE, Pamir N, von Haller PD, et al. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. *J Proteomics*. 2015;113:388-399.
 114. Thompson A, Schafer J, Kuhn K, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. *Anal Chem*. 2003;75(8):1895-1904.
 115. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. *Mol Cell Proteomics*. 2012;11(6):O111 016717.
 116. Schubert OT, Gillet LC, Collins BC, et al. Building high-quality assay libraries for targeted analysis of SWATH MS data. *Nat Protoc*. 2015;10(3):426-441.
 117. Nahnsen S, Bielow C, Reinert K, Kohlbacher O. Tools for label-free peptide quantification. *Mol Cell Proteomics*. 2013;12(3):549-556.
 118. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in *Saccharomyces cerevisiae* using amine-reactive isobaric tagging reagents. *Mol Cell Proteomics*. 2004;3(12):1154-1169.
 119. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol Cell Proteomics*. 2002;1(5):376-386.
 120. Cho JL, Ling MF, Adams DC, et al. Allergic asthma is distinguished by sensitivity of allergen-specific CD4+ T cells and airway structural cells to type 2 inflammation. *Sci Transl Med*. 2016;8(359):359ra132.
 121. Tomazic PV, Liesinger L, Pucher B, et al. Comparison of tear proteome in allergic rhinoconjunctivitis patients and controls with respect to pollen season. *Allergy*. 2018;73(7):1541-1543.
 122. Morelli P, Gaspari M, Gabriele C, et al. Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. *Exp Dermatol*. 2021;30(6):811-819.
 123. Schofield JPR, Burg D, Nicholas B, et al. Stratification of asthma phenotypes by airway proteomic signatures. *J Allergy Clin Immunol*. 2019;144(1):70-82.
 124. Nieto-Fontarigo JJ, Gonzalez-Barcala FJ, Andrade-Bulos LJ, et al. iTRAQ-based proteomic analysis reveals potential serum biomarkers of allergic and nonallergic asthma. *Allergy*. 2020;75(12):3171-3183.
 125. Zounemat Kermani N, Saqi M, Agapov P, et al. Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics. *Allergy*. 2021;76(1):380-383.
 126. Hou T, Tsang MS, Chu IM, et al. Skewed inflammation is associated with aberrant interleukin-37 signaling pathway in atopic dermatitis. *Allergy*. 2021;76(7):2102-2114.
 127. Chen X, Xie ZH, Lv YX, et al. A proteomics analysis reveals that A2M might be regulated by STAT3 in persistent allergic rhinitis. *Clin Exp Allergy*. 2016;46(6):813-824.
 128. Funke L, Gnipp S, Ahrens M, et al. Quantitative analysis of proteome dynamics in a mouse model of asthma. *Clin Exp Allergy*. 2021;51(11):1471-1481.
 129. Celi G, Brusca I, Scala E, et al. House dust mite allergy in Italy: diagnostic and clinical relevance of Der p 23 (and of minor allergens): a real-life, multicenter study. *Allergy*. 2019;74(9):1787-1789.

130. Barbero N, Fernandez-Santamaria R, Mayorga C, et al. Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions. *Allergy*. 2019;74(8):1490-1501.
131. Poncet P, Senechal H, Clement G, et al. Evaluation of ash pollen sensitization pattern using proteomic approach with individual sera from allergic patients. *Allergy*. 2010;65(5):571-580.
132. Messina A, Palmigiano A, Tosto C, et al. Tear N-glycomics in vernal and atopic keratoconjunctivitis. *Allergy*. 2021;76(8):2500-2509.
133. Emmert H, Baurecht H, Thielking F, et al. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. *Exp Dermatol*. 2021;30(10):1398-1408.
134. Elias MS, Wright SC, Remenyi J, et al. EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis. *J Allergy Clin Immunol*. 2019;144(2):470-481.
135. Kolmert J, Gomez C, Balgoma D, et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study. *Am J Respir Crit Care Med*. 2021;203(1):37-53.
136. James BN, Oyeniran C, Sturgill JL, et al. Ceramide in apoptosis and oxidative stress in allergic inflammation and asthma. *J Allergy Clin Immunol*. 2021;147(5):1936-1948 e1939.
137. Kemter AM, Nagler CR. Influences on allergic mechanisms through gut, lung, and skin microbiome exposures. *J Clin Invest*. 2019;129(4):1483-1492.
138. Mathieu E, Escribano-Vazquez U, Descamps D, et al. Paradigms of lung microbiota functions in health and disease, particularly, in asthma. *Front Physiol*. 2018;9:1168.
139. Marrs T, Flohr C. The role of skin and gut microbiota in the development of atopic eczema. *Br J Dermatol*. 2016;175(Suppl 2):13-18.
140. Spertini F. Metabolomics and allergy: opening Pandora's box. *J Allergy Clin Immunol*. 2020;145(3):782-784.
141. Lee-Sarwar KA, Lasky-Su J, Kelly RS, Litonjua AA, Weiss ST. Gut microbial-derived metabolomics of asthma. *Metabolites*. 2020;10(3):97.
142. Stuart T, Satija R. Integrative single-cell analysis. *Nat Rev Genet*. 2019;20(5):257-272.
143. Hu P, Zhang W, Xin H, Deng G. Single cell isolation and analysis. *Front Cell Dev Biol*. 2016;4:116-116.
144. Lähnemann D, Köster J, Szczurek E, et al. Eleven grand challenges in single-cell data science. *Genome Biology*. 2020;21(1):31.
145. Vrijheid M. The exposome: a new paradigm to study the impact of environment on health. *Thorax*. 2014;69(9):876-878.
146. Zhang P, Carlsten C, Chaleckis R, et al. Defining the scope of exposome studies and research needs from a multidisciplinary perspective. *Environ Sci Technol Lett*. 2021;8(10):839-852.
147. Vineis P, Chadeau-Hyam M, Gmuender H, et al. The exposome in practice: design of the EXPOsOMICS project. *Int J Hyg Environ Health*. 2017;220(2 Pt A):142-151.
148. Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE. Thinking bigger: how early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease. *Allergy*. 2019;74(11):2103-2115.
149. Jiang C, Zhang X, Gao P, Chen Q, Snyder M. Decoding personal biotic and abiotic airborne exposome. *Nat Protoc*. 2021;16(2):1129-1151.
150. Jeong A, Fiorito G, Keski-Rahkonen P, et al. Perturbation of metabolic pathways mediates the association of air pollutants with asthma and cardiovascular diseases. *Environ Int*. 2018;119:334-345.
151. Lopez-Cervantes JP, Lonnebotn M, Jogi NO, et al. The exposome approach in allergies and lung diseases: is it time to define a preconception exposome? *Int J Environ Res Public Health*. 2021;18(23):12684.
152. Kim M, Tagkopoulos I. Data integration and predictive modeling methods for multi-omics datasets. *Mol Omics*. 2018;14(1):8-25.
153. Lopez de Maturana E, Alonso L, Alarcon P, et al. Challenges in the integration of omics and non-omics data. *Genes (Basel)*. 2019;10(3):238.
154. Jayawardana K, Schramm SJ, Haydu L, et al. Determination of prognosis in metastatic melanoma through integration of clinicopathologic, mutation, mRNA, microRNA, and protein information. *Int J Cancer*. 2015;136(4):863-874.
155. Raita Y, Perez-Losada M, Freishtat RJ, et al. Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma. *Nat Commun*. 2021;12(1):3601.
156. Raita Y, Camargo CA Jr, Bochkov YA, et al. Integrated-omics endotyping of infants with rhinovirus bronchiolitis and risk of childhood asthma. *J Allergy Clin Immunol*. 2021;147(6):2108-2117.
157. Delgado-Dolset MI, Obeso D, Rodriguez-Coira J, et al. Understanding uncontrolled severe allergic asthma by integration of omic and clinical data. *Allergy*. 2021;77(6):1772-1785.
158. Lee B, Zhang S, Poleksic A, Xie L. Heterogeneous multi-layered network model for omics data integration and analysis. *Front Genet*. 2019;10:1381.
159. Subramanian I, Verma S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. *Bioinform Biol Insights*. 2020;14:1177932219899051.
160. Hinks TSC, Brown T, Lau LCK, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. *J Allergy Clin Immunol*. 2016;138(1):61-75.
161. Agache I, Strasser DS, Pierlot GM, Farine H, Izuhara K, Akdis CA. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. *J Allergy Clin Immunol*. 2018;141(1):442-445.
162. Abdel-Aziz MI, Brinkman P, Vijverberg SJH, et al. eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. *J Allergy Clin Immunol*. 2020;146(5):1045-1055.
163. Ghosh D, Ding L, Bernstein JA, Mersha TB. The utility of resolving asthma molecular signatures using tissue-specific transcriptome data. *G3 (Bethesda)*. 2020;10(11):4049-4062.
164. Fontanella S, Frainay C, Murray CS, Simpson A, Custovic A. Machine learning to identify pairwise interactions between specific IgE antibodies and their association with asthma: a cross-sectional analysis within a population-based birth cohort. *PLoS Med*. 2018;15(11):e1002691.
165. Kuruvilla R, Scott K, Pirmohamed SM. Pharmacogenomics of drug hypersensitivity: technology and translation. *Immunol Allergy Clin North Am*. 2022;42(2):335-355.
166. Farzan N, Vijverberg SJ, Hernandez-Pacheco N, et al. 17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. *Allergy*. 2018;73(10):2083-2088.
167. Hawcutt DB, Francis B, Carr DF, et al. Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. *Lancet Respir Med*. 2018;6(6):442-450.
168. Vijverberg SJH, Farzan N, Slob EMA, Neerinx AH, Maitland-van der Zee AH. Treatment response heterogeneity in asthma: the role of genetic variation. *Expert Rev Respir Med*. 2018;12(1):55-65.
169. Slob EMA, Vijverberg SJH, Palmer CNA, et al. Pharmacogenetics of inhaled long-acting beta2-agonists in asthma: a systematic review. *Pediatr Allergy Immunol*. 2018;29(7):705-714.
170. Turner S, Francis B, Vijverberg S, et al. Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: a meta-analysis stratified by treatment. *J Allergy Clin Immunol*. 2016;138(1):107-113 e105.
171. Barker-Tejeda TC, Bazire R, Obeso D, et al. Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics. *Allergy*. 2021;76(4):1199-1212.
172. Obeso D, Mera-Berriatua L, Rodriguez-Coira J, et al. Multi-omics analysis points to altered platelet functions in severe food-associated respiratory allergy. *Allergy*. 2018;73(11):2137-2149.

173. Zheng P, Bian X, Zhai Y, et al. Metabolomics reveals a correlation between hydroxyecosatetraenoic acids and allergic asthma: evidence from three years' immunotherapy. *Pediatr Allergy Immunol.* 2021;32(8):1654-1662.
174. Rago D, Pedersen CT, Huang M, et al. Characteristics and mechanisms of a sphingolipid-associated childhood asthma endotype. *Am J Respir Crit Care Med.* 2021;203(7):853-863.
175. McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. *BMC Med.* 2013;11:220.
176. McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. *Nature.* 2013;502(7471):317-320.
177. Holmes C, McDonald F, Jones M, Ozdemir V, Graham JE. Standardization and omics science: technical and social dimensions are inseparable and demand symmetrical study. *OMICS.* 2010;14(3):327-332.
178. Levesque E, Kirby E, Bolt I, et al. Ethical, legal, and regulatory issues for the implementation of omics-based risk prediction of women's cancer: points to consider. *Public Health Genomics.* 2018;21(1-2):37-44.
179. D'Adamo GL, Widdop JT, Giles EM. The future is now? Clinical and translational aspects of "Omics" technologies. *Immunol Cell Biol.* 2021;99(2):168-176.
180. Krassowski M, Das V, Sahu SK, Misra BB. State of the field in multi-omics research: from computational needs to data mining and sharing. *Front Genet.* 2020;11:610798.
181. Wang S, Cheng Q. Microarray Analysis in Drug Discovery and Clinical Applications. In: Larson RS, ed. *Bioinformatics and Drug Discovery.* Humana Press; 2006:49-65.
182. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet.* 2008;9(5):356-369.
183. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. *Nat Rev Genet.* 2009;10(5):318-329.
184. Lamprecht A-L. Microarray Data Analysis Pipelines. In: Lamprecht A-L, ed. *User-Level Workflow Design.* Springer Berlin Heidelberg; 2013:119-137.
185. Loewe RP, Nelson PJ. Microarray Bioinformatics. In: Khademhosseini A, Suh K-Y, Zourob M, eds. *Biological Microarrays: Methods and Protocols.* Humana Press; 2011:295-320.
186. Bjornsdottir US, Holgate ST, Reddy PS, et al. Pathways activated during human asthma exacerbation as revealed by gene expression patterns in blood. *PLoS One.* 2011;6(7):e21902.
187. Ferreira MA, Matheson MC, Tang CS, et al. Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. *J Allergy Clin Immunol.* 2014;133(6):1564-1571.
188. Waage J, Standl M, Curtin JA, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. *Nat Genet.* 2018;50(8):1072-1080.
189. Owens NDL, De Domenico E, Gilchrist MJ. An RNA-Seq protocol for differential expression analysis. *Cold Spring Harb Protoc.* 2019;2019(6):pdb.prot098368.
190. Yalamanchili HK, Wan YW, Liu Z. Data analysis pipeline for RNA-seq experiments: from differential expression to cryptic splicing. *Curr Protoc Bioinformatics.* 2017;59:11.15.11-11.15.21.
191. Watson CT, Cohain AT, Griffin RS, et al. Integrative transcriptomic analysis reveals key drivers of acute peanut allergic reactions. *Nat Commun.* 2017;8(1):1943.
192. Yang M, Xiong M, Chen H, et al. Novel genetic variants associated with child refractory esophageal stricture with food allergy by exome sequencing. *Nutrients.* 2017;9(4):390.
193. Velazquez-Villarreal EI, Maheshwari S, Sorenson J, et al. Single-cell sequencing of genomic DNA resolves sub-clonal heterogeneity in a melanoma cell line. *Commun Biol.* 2020;3(1):318.
194. Hwang B, Lee JH, Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines. *Exp Mol Med.* 2018;50(8):1-14.
195. Yip SH, Sham PC, Wang J. Evaluation of tools for highly variable gene discovery from single-cell RNA-seq data. *Brief Bioinform.* 2019;20(4):1583-1589.
196. Yan H, Evans J, Kalmbach M, et al. HiChIP: a high-throughput pipeline for integrative analysis of ChIP-Seq data. *BMC Bioinformatics.* 2014;15(1):280.
197. Yan F, Powell DR, Curtis DJ, Wong NC. From reads to insight: a hitchhiker's guide to ATAC-seq data analysis. *Genome Biol.* 2020;21(1):22.
198. Shahryary Y, Hazarika RR, Johannes F. MethylStar: a fast and robust pre-processing pipeline for bulk or single-cell whole-genome bisulfite sequencing data. *BMC Genomics.* 2020;21(1):479.
199. Yu M, Hon GC, Szulwach KE, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. *Cell.* 2012;149(6):1368-1380.
200. Zhu Q, Liu N, Orkin SH, Yuan GC. CUT&RUNTools: a flexible pipeline for CUT&RUN processing and footprint analysis. *Genome Biol.* 2019;20(1):192.
201. Lu C, Coradin M, Porter EG, Garcia BA. Accelerating the field of epigenetic histone modification through mass spectrometry-based approaches. *Mol Cell Proteomics.* 2021;20:100006.
202. Li J, Kho AT, Chase RP, et al. COMPSRA: a COMprehensive platform for small RNA-Seq data analysis. *Sci Rep.* 2020;10(1):4552.
203. Sun Z, Nair A, Chen X, Prodduturi N, Wang J, Kocher JP. UCLncR: ultrafast and comprehensive long non-coding RNA detection from RNA-seq. *Sci Rep.* 2017;7(1):14196.
204. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protoc.* 2007;2(11):2692-2703.
205. Kirwan JA, Brennan L, Broadhurst D, et al. Preanalytical processing and biobanking procedures of biological samples for metabolomics research: a white paper, community perspective (for "Precision Medicine and Pharmacometabolomics Task Group"-the metabolomics society initiative). *Clin Chem.* 2018;64(8):1158-1182.
206. Crestani E, Harb H, Charbonnier LM, et al. Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma. *J Allergy Clin Immunol.* 2020;145(3):897-906.
207. Want EJ, Masson P, Michopoulos F, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. *Nat Protoc.* 2013;8(1):17-32.
208. Hernandez VV, Barbas C, Dudzik D. A review of blood sample handling and pre-processing for metabolomics studies. *Electrophoresis.* 2017;38(18):2232-2241.
209. Kelly RS, Dahlin A, McGeachie MJ, et al. Asthma metabolomics and the potential for integrative omics in research and the clinic. *Chest.* 2017;151(2):262-277.
210. Garcia A, Barbas C. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics. *Methods Mol Biol.* 2011;708:191-204.
211. Dudzik D, Barbas-Bernardos C, Garcia A, Barbas C. Quality assurance procedures for mass spectrometry untargeted metabolomics. a review. *J Pharm Biomed Anal.* 2018;147:149-173.
212. Reinke SN, Gallart-Ayala H, Gomez C, et al. Metabolomics analysis identifies different metabolotypes of asthma severity. *Eur Respir J.* 2017;49(3):1601740.
213. Garcia A, Naz S, Barbas C. Metabolite fingerprinting by capillary electrophoresis-mass spectrometry. *Methods Mol Biol.* 2014;1198:107-123.
214. Gil-de-la-Fuente A, Godzien J, Saugar S, et al. CEU mass mediator 3.0: a metabolite annotation tool. *J Proteome Res.* 2019;18(2):797-802.
215. Naz S, Moreira dos Santos DC, Garcia A, Barbas C. Analytical protocols based on LC-MS, GC-MS and CE-MS for

- nontargeted metabolomics of biological tissues. *Bioanalysis*. 2014;6(12):1657-1677.
216. Montenegro-Burke JR, Guijas C, Siuzdak G. METLIN: a tandem mass spectral library of standards. *Methods Mol Biol*. 2020;2104:149-163.
217. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat Protoc*. 2011;6(7):1060-1083.
218. Domingo-Almenara X, Montenegro-Burke JR, Ivanisevic J, et al. XCMS-MRM and METLIN-MRM: a cloud library and public resource for targeted analysis of small molecules. *Nat Methods*. 2018;15(9):681-684.
219. Ono JG, Kim BI, Zhao Y, et al. Decreased sphingolipid synthesis in children with 17q21 asthma-risk genotypes. *J Clin Invest*. 2020;130(2):921-926.
220. Kyle JE. Extracting biological insight from untargeted lipidomics data. *Methods Mol Biol*. 2020;2104:121-137.
221. Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. *Nat Methods*. 2015;12(6):523-526.
222. Chong J, Wishart DS, Xia J. Using metaboanalyst 4.0 for comprehensive and integrative metabolomics data analysis. *Curr Protoc Bioinformatics*. 2019;68(1):e86.
223. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol*. 2016;17(7):451-459.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Radzikowska U, Baerenfaller K, Cornejo-Garcia JA, et al. Omics technologies in allergy and asthma research: An EAACI position paper. *Allergy*. 2022;77:2888-2908. doi: [10.1111/all.15412](https://doi.org/10.1111/all.15412)